N-1-13C-Hexadecanoyl-sphingosylphosphorylcholine

H2200

N-1-13C-Hexadecanoyl-sphingosylphosphorylcholine

semisynthetic

12C₃₈13CH₇₉N₂O₆P

703

1mg

solid

98+% TLC

D-erythro-Spingomyelin with 1-13C-palmitic acid; N-1-13C-Palmitoyl-sphingosylphosphorylcholine

chloroform, methanol, ethanol

-20°C

1. R. N. Kolesnick, A. Haimovitz-Friedman, Z. Fuks “The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation” Biochem Cell Biol., Vol. 72(11-12) pp. 471-474, 1994
2. M. Schmuth, et al. “Permeability barrier disorder in Niemann-Pick disease: sphingomyelin-ceramide processing required for normal barrier homeostasis” J Invest Dermatol., Vol. 115(3) pp. 459-466, 2000
3. C. St Clair et al. “The probability of neonatal respiratory distress syndrome as a function of gestational age and lecithin/sphingomyelin ratio” Am J Perinatol., Vol. 25(8) pp. 473-480, 2008,
4. J. Kilkus et al. “Differential regulation of sphingomyelin synthesis and catabolism in oligodendrocytes and neurons” J Neurochem. Vol. 106(4) pp. 1745- 1757, 2008
5. N. Duan RD. “Absorption and lipoprotein transport of sphingomyelin” J Lipid Res., Vol. 47(1) pp. 154-171, 2006
6. R. Veldman et al. “N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx” Nature, Vol. 90 pp. 917-925, 2004